Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Evaluate Vantage Homepage
Pharmaceutical Companies
Resverlogix
December 19, 2014
Merck & Co gives epigenetics a boost
November 12, 2014
Debt-funded biotechs under the spotlight
January 08, 2014
Small cap biotechs reap rewards of the bull market in 2013
October 02, 2013
US outperformance dominates small-cap drug stock gains
July 04, 2013
Japan continues to dominate small cap risers but US biotech muscles in
June 28, 2013
Resverlogix doomed by second failure
July 20, 2012
Key data readouts in the second half of 2012
May 08, 2012
Roche’s dalcetrapib failure not end of the road for CETP
September 08, 2011
Vantage Point - Functionality in focus as HDL hypothesis awaits confirmation
November 18, 2010
AHA 2010 – Debate over benefits of raising HDL set to continue
November 18, 2010
AHA 2010 – Resverlogix falls back to earth
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
April 20, 2022
Genetic Medicine: The Next Generation
March 18, 2022
PD(L)anner - March 2022
Editor's Picks
May 05, 2022
Bristol needs to get fresh
May 04, 2022
The next generation of diabetes technology
April 25, 2022
Nkarta: at least as good as Fate, at a tenth of the price
April 26, 2022
How Gal appointment could influence strategy at Novartis
May 01, 2020
US FDA approval tracker: April
